Table 4.

Conditional Logistic Regression comparing Characteristics of SLE in Adult MAS cases and Matched Hospitalized SLE Patients without MAS, Odds Ratios and 95% Confidence Intervals (95%CI) ^*

	Univariable Models, OR and 95%CI (N=106)	Multivariable Models, OR and 95%CI (N=106)‡
Age at SLE diagnosis (years)	1.00 (0.96–1.02)	1.00 (0.95–1.05)
Age at admission (years)	1.00 (0.96–1.03)
Female	0.71 (0.23–2.18)	3.51 (0.46–26.45)
Median Income	0.99 (0.99–1.01)
Asian	1.77 (0.44–7.23)
Black	1.94 (0.75– 5.00)
Hispanic/Latino	0.63 (0.07–5.89)
Other	0.48 (0.06–4.01)
White	0.60 (0.22–1.65)
Number of ACR criteria at time of hospitalization	1.06 (0.84–1.35)
SLEDAI score on admission	1.07 (1.02–1.11)	1.10 (1.02–1.19)
Malar rash	1.41 (0.53–3.76)
Discoid lesions	1.24 (0.39–3.92)
Photosensitivity	0.95 (0.36–2.52)
Oral ulcers	1.21 (0.41–3.59)
Arthritis	0.25 (0.09–0.71)	0.04 (0.004–0.35)
Serositis	0.66 (0.26–1.71)
Renal involvement	2.15 (0.78–5.92)
CNS involvement	1.45 (0.45–4.64)
Hematologic	4.59 (1.04–20.3)
Immunologic disorders	1.32 (0.46–3.78)
Antinuclear antibody	0.63 (0.12–3.22)
Medications upon admission‡
Hydroxychloroquine	0.25 (0.09–0.70)	0.18 (0.04–0.72)
Prednisone	1.40 (0.57–3.42)
Azathioprine or 6-MP	0.80 (0.09–6.85)
Mycophenolate mofetil	0.40 (0.05–3.45)
Methotrexate	2.00 (0.18–22.06)

^*Cases and controls matched on year of SLE diagnosis

^‡Age, sex and variables with p<0.10 (SLEDAI score, arthritis and hydroxychloroquine on admission) were included in the multivariable model (empty cell if variable not included in analysis).

^‡Rituximab, cyclophosphamide, anakinra, cyclosporine, tacrolimus and IVIG omitted from the analysis as numbers too small.